AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
August 18, 2021- In the atogepant Phase 3 ADVANCE trial, participants experienced a significant reduction in migraine and headache days across 12 weeks of treatment¹
-
August 09, 2021- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe
-
August 04, 2021- Upadacitinib (30 mg, once daily) monotherapy demonstrated significantly greater rates of skin clearance improvement and itch reduction compared to dupilumab (300 mg, every other week) monotherapy at 16 weeks[1]
-
July 30, 2021- Reports Second-Quarter Diluted EPS of $0.42 on a GAAP Basis; Adjusted Diluted EPS of $3.11
-
July 29, 2021-- 6.7 million adults in the U.S. are living with spasticity across a variety of neurologic conditions
-
July 27, 2021- Extension builds on partnership established in 2014, extended in 2018
-
July 25, 2021- If approved, AGN-190584 is expected to be the first eye drop for the treatment of presbyopia, the eye's reduced ability to focus on near objects
-
July 23, 2021- DALVANCE® is the first and only single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth
-
July 21, 2021- This is the sixth BTD granted for venetoclax as AbbVie continues to show ongoing commitment across blood cancers including tough to treat myeloid malignancies
-
July 20, 2021- Data presentations highlight Phase 3 GEMINI 1 trial results on the safety and efficacy of investigational AGN-190584 (pilocarpine 1.25%) as a potential novel treatment for presbyopia, a common and progressive eye condition that reduces the eye's ability to focus on near objects
-
June 29, 2021- Significantly more upadacitinib-treated (15 mg or 30 mg, once daily) patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to patients on placebo at one-year (week 52) (p<0.001)[1]
-
June 25, 2021- Positive opinion based on three global Phase 3 pivotal studies evaluating the safety and efficacy of RINVOQ (15 mg or 30 mg, once daily) used with or without topical corticosteroids in adults and adolescents with moderate to severe atopic dermatitis[1],[2]
-
June 17, 2021
-
June 12, 2021- All-oral, once-daily, chemotherapy-free, fixed-duration ibrutinib plus venetoclax (I+V) combination met its primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC); I+V reduced the risk of disease progression or death by 78% compared to chlorambucil plus obinutuzumab (C+O)
-
June 11, 2021- Four-year follow-up analysis of Phase 3 CLL14 trial (median follow-up 52.4 months), continues to demonstrate longer progression-free survival (PFS) after fixed-duration venetoclax plus obinutuzumab compared to fixed duration chlorambucil plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL)
-
June 08, 2021BRAND UNVEILS 'SEE YOURSELF' DOCUMENTARY STYLE CONTENT SERIES HIGHLIGHTING THE PEOPLE WHO GET TREATED WITH BOTOX® COSMETIC AND THEIR REASON WHY
-
June 07, 2021- The fixed-duration combination met the primary endpoint of complete response rate at 56% among patients with previously untreated CLL, 70 years old or younger
-
June 04, 2021- With up to seven years of data, progression-free and overall survival benefits continue to be observed with first-line single-agent IMBRUVICA treatment in CLL patients including selected patients with or without high-risk genomic features
-
June 02, 2021- In Crohn's disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical remission at one year (52 weeks) versus those who were withdrawn from risankizumab (control group)[1]
-
June 02, 2021- In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2]
-
June 02, 2021- Long-term data from the Phase 3 SELECT-COMPARE trial show that continuous treatment with RINVOQ (upadacitinib, 15 mg, once-daily) plus MTX maintained rates of clinical remission and low disease activity through three years in adults with rheumatoid arthritis[1]
-
May 26, 2021-- Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine are among several abstracts
-
May 25, 2021-- VENCLYXTO® (venetoclax) in combination with a hypomethylating agent is a new regimen approved by the European Commission (EC) for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy [1]
-
May 25, 2021- First presentation of three-year data from Phase 3 SELECT-COMPARE study assessing long-term efficacy and safety of RINVOQ® (upadacitinib) versus HUMIRA® (adalimumab) in patients with rheumatoid arthritis (RA)
-
May 24, 2021- In the ADVANCE trial, risankizumab (SKYRIZI) met co-primary endpoints of clinical remission and endoscopic response compared to placebo at 12 weeks in patients with intolerance or inadequate response to conventional and/or biologic therapy[1]
-
May 19, 2021-- 43 abstracts on six investigational and approved medicines across 12 cancer types to be presented at both meetings
-
May 10, 2021-- Acquisition adds Rapid Acoustic Pulse technology platform for improvement in appearance of cellulite in the buttocks and thighs --
-
April 30, 2021- Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95
-
April 27, 2021- New analyses of Phase 3 ARTEMIS studies provide further insights on duration and biodegradation of DURYSTA™ (bimatoprost intracameral implant)
-
April 23, 2021- Positive opinion based on data from the VIALE-A and M14-358 trials, which evaluated the safety, efficacy and pharmacokinetics of VENCLYXTO in combination with hypomethylating agents in adult patients with AML
-
April 07, 2021- Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo[1]
-
April 07, 2021-- Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine to be presented at the Clinical Trials Plenary Session; study was also only headache topic to earn Merit of Distinction in 2021
-
April 01, 2021Revolutionary, Clinically Proven Product Addresses Multi-Factorial Causes & Symptoms of Neck Aging
-
April 01, 2021- In SELECT-PsA 1, RINVOQ™ (upadacitinib, 15 mg and 30 mg) improved key joint and skin symptoms up to 24 weeks, including enthesitis[1]
-
March 31, 2021
-
March 30, 2021- If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine[1]
-
February 25, 2021- If approved, this is expected to be the first eye drop to treat presbyopia
-
February 24, 2021- HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis[1]
-
February 22, 2021- 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p<0.001)[1]
-
February 19, 2021
-
February 18, 2021
-
February 10, 2021- Collaboration leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders
-
February 10, 2021-- Children living with neurogenic detrusor overactivity who are not adequately managed with anticholinergic medication now have a new treatment option prior to surgical intervention
-
February 03, 2021- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56
-
January 26, 2021NEW TECHNOLOGY ALLOWS FOR THE TREATMENT OF TWO AREAS OF FAT AT ONCE AND NEW ELITE APPLICATORS DESIGNED FOR IMPROVED FIT AND COMFORT
-
January 25, 2021- RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2]
-
January 15, 2021- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications
-
January 12, 2021-- Agreement Includes Development of Xact Device, a Minimally-Invasive Alternative Option for Performing Face and Neck Lifts --
-
January 07, 2021- A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab (600 mg or 1200 mg) achieved both primary endpoints, demonstrating statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo[1,2]
-
January 05, 2021- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo (p<0.001)[1]
-
December 23, 2020- Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM
-
December 11, 2020- Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoid arthritis (RA)[1-4]
-
December 10, 2020- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1]
-
December 09, 2020- Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe ulcerative colitis[1]
-
December 05, 2020- New five-year, follow-up analysis from the Phase 3 MURANO trial shows median progression-free survival (PFS) of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab compared to 17.0 months in patients taking bendamustine plus rituximab (BR) after three years or more off treatment[1]
-
December 02, 2020- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases
-
December 01, 2020
-
November 16, 2020NUMBER 1 SELLING PRODUCT OF ITS KIND CELEBRATES BOTH LOYAL AND NEW CONSUMERS WITH EXCLUSIVE OFFER ON NOVEMBER 18th
-
November 12, 2020
-
November 05, 2020- Nearly 40 abstracts on eight investigational and approved products across 11 cancer types to be presented
-
October 30, 2020- Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis; Adjusted Diluted EPS of $2.83
-
October 29, 2020-- New RINVOQ analyses from the Measure Up 1 and 2 monotherapy studies show improvements in additional measures of skin clearance, itch and quality of life in adult and adolescent patients with moderate to severe atopic dermatitis[1]
-
October 28, 2020- Researchers to share updates on long-term safety and efficacy of RINVOQ for the treatment of moderate to severe rheumatoid arthritis
-
October 28, 2020- Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly four out of 10 people in the U.S.
-
October 19, 2020- In three pivotal Phase 3 studies, RINVOQ met co-primary and all secondary endpoints in adult and adolescent patients with moderate to severe atopic dermatitis[1-3]
-
October 16, 2020- The FDA approval of VENCLEXTA for newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a series of trials including two Phase 3 trials - VIALE-A (M15-656) and VIALE-C (M16-043)
-
October 07, 2020-- Acquisition Immediately Enhances Allergan Aesthetics' Leading International Dermal Filler Portfolio & Pipeline --
-
October 06, 2020
-
October 02, 2020- New data from Phase 3 ADVANCE trial evaluating investigational medicine atogepant for the preventive treatment of migraine accepted for oral presentation
-
September 28, 2020- Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury
September 16, 2020Partnership will educate on body contouring options and encourage consumers to "Shape Your Moment" with CoolSculpting®-
September 11, 2020- Final data from the 12-week DYSCOVER study, the first randomized trial of DUODOPA® (levodopa/carbidopa intestinal gel) on the duration and severity of dyskinesia in patients with advanced Parkinson's disease
-
September 11, 2020
-
September 04, 2020AbbVie and I-Mab to collaborate on development and commercialization of I-Mab's highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)
-
September 03, 2020
-
August 25, 2020- RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis[1]
-
August 12, 2020- Data from Phase 3 VIALE-A study showed venetoclax plus azacitidine reduced the risk of death by 34% compared to azacitidine plus placebo in newly-diagnosed patients with AML who are ineligible for chemotherapy
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
